Published in Br J Cancer on May 01, 1999
Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol (2005) 10.99
Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer (2010) 1.46
Role of hematopoietic growth factors as adjuncts in the treatment of chronic hepatitis C patients. Saudi J Gastroenterol (2008) 1.00
Erythropoietin, uncertainty principle and cancer related anaemia. BMC Cancer (2002) 0.96
Effects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished data. Br J Cancer (2014) 0.90
Treatment-induced anaemia and its potential clinical impact in patients receiving sequential high dose chemotherapy for metastatic testicular cancer. Br J Cancer (2002) 0.85
Pleiotrophic actions of erythropoietin. Environ Health Prev Med (2003) 0.75
Dose reduction of epoetin-alpha in the prevention of chemotherapy-induced anaemia. Support Care Cancer (2009) 0.75
Reporting results of cancer treatment. Cancer (1981) 28.83
Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med (1987) 5.57
Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol (1997) 2.41
Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med (1990) 2.11
Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol (1997) 1.87
Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet (1992) 1.80
Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med (1990) 1.72
Special report: transfusion risks. Am J Clin Pathol (1987) 1.48
Effects of transfusion on immune function. Cancer recurrence and infection. Arch Pathol Lab Med (1994) 1.33
Carboplatin: the clinical spectrum to date. Cancer Treat Rev (1985) 1.27
Blunted erythropoietin response to anaemia in rheumatoid arthritis. Br J Haematol (1987) 1.23
The frequency of red cell transfusion for anemia in patients receiving chemotherapy. A retrospective cohort study. Am J Clin Oncol (1993) 1.18
Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst (1993) 1.11
Cisplatin-associated anaemia treated with subcutaneous erythropoietin. A pilot study. Br J Cancer (1993) 1.08
Erythropoietin for anaemia in cancer patients. Eur J Cancer (1993) 1.08
Effect of cis-diamminedichloroplatinum on erythropoietin production and hematopoietic progenitor cells. Int J Cell Cloning (1985) 0.95
Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer. J Clin Oncol (1995) 0.94
Cisplatin-induced anemia. N Engl J Med (1980) 0.90
Erythropoietin treatment of chronic anaemia of cancer. Eur J Cancer (1993) 0.85
Recombinant human erythropoietin for the treatment of chronic anemia in multiple myeloma and squamous cell carcinoma. Stem Cells (1993) 0.85
The in vitro effect of recombinant erythropoietin on cisdiamminodichloroplatinum-induced inhibition of murine erythroid stem cells. Anticancer Res (1991) 0.82
Treatment of advanced non-small cell lung cancer with cisplatin, 5-fluorouracil, and mitomycin C. Cancer (1988) 0.82
Extension of life-span by loss of CHICO, a Drosophila insulin receptor substrate protein. Science (2001) 7.85
Drosophila S6 kinase: a regulator of cell size. Science (1999) 6.76
An evolutionarily conserved function of the Drosophila insulin receptor and insulin-like peptides in growth control. Curr Biol (2001) 6.15
Autonomous control of cell and organ size by CHICO, a Drosophila homolog of vertebrate IRS1-4. Cell (1999) 5.38
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol (2001) 5.25
Curcumin: the story so far. Eur J Cancer (2005) 4.17
Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet (1998) 4.16
Oligomerization of mu- and delta-opioid receptors. Generation of novel functional properties. J Biol Chem (2000) 3.22
Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. N Engl J Med (1992) 3.21
CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest (2000) 3.17
Strongyloides stercoralis infection in former Far East prisoners of war. Br Med J (1979) 2.91
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol (2002) 2.87
Structure and function of heparan sulphate proteoglycans. Biochem J (1986) 2.78
Primary mediastinal B-cell lymphoma with sclerosis: an aggressive tumor with distinctive clinical and pathologic features. J Clin Oncol (1993) 2.77
Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res (2001) 2.69
Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol (1997) 2.41
Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J Natl Cancer Inst (1996) 2.41
Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy. Cancer (1995) 2.38
No standard treatment is available for advanced pancreatic cancer. Eur J Cancer (1995) 2.23
Molecular prognostic markers in pancreatic cancer: a systematic review. Eur J Cancer (2005) 2.20
Water in Earth's Mantle: The Role of Nominally Anhydrous Minerals. Science (1992) 2.19
Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance. J Clin Oncol (1985) 2.12
Gemcitabine--a major advance? Ann Oncol (1998) 2.05
Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol (1999) 1.98
Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer (2004) 1.97
Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer (1997) 1.93
Patterns of alternative medicine use by cancer patients. Med J Aust (1996) 1.90
PDK1 regulates growth through Akt and S6K in Drosophila. Proc Natl Acad Sci U S A (2001) 1.85
Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann Oncol (2000) 1.79
Performance status and comorbidity in elderly cancer patients compared with young patients with neoplasia and elderly patients without neoplastic conditions. Cancer (1998) 1.76
Multidrug resistance. Cancer Surv (1986) 1.75
Psychosocial factors in chronic spinal cord injury pain. Pain (1991) 1.71
The diagnostic value of the neutrophil left shift in predicting inflammatory and infectious disease. Am J Clin Pathol (1997) 1.71
Persisting nutritional neuropathy amongst former war prisoners. J Neurol Neurosurg Psychiatry (1982) 1.67
P-glycoprotein in human sarcoma: evidence for multidrug resistance. J Clin Oncol (1987) 1.64
Combined use of cyclosporin A and verapamil in modulating multidrug resistance in human leukemia cell lines. Cancer Res (1990) 1.61
Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer (2000) 1.57
Genetic control of size in Drosophila. Philos Trans R Soc Lond B Biol Sci (2000) 1.55
Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer). Ann Oncol (2005) 1.54
Adjuvant chemotherapy in the treatment of colon cancer: randomized multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC). Ann Oncol (2003) 1.52
Inhaled steroids in patients with bronchiectasis. Respir Med (1992) 1.51
Strongyloidiasis in ex-Far East prisoners of war. Br Med J (1977) 1.49
Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter? J Clin Oncol (1999) 1.47
Detection of a multidrug resistant phenotype in acute non-lymphoblastic leukaemia. Lancet (1987) 1.47
Role of inflammation in pancreatic carcinogenesis and the implications for future therapy. Pancreatology (2005) 1.47
Serum osteocalcin and bone mineral density at various skeletal sites: a study performed with three different assays. J Lab Clin Med (1997) 1.43
Transdermal fentanyl in uncontrolled cancer pain: titration on a day-to-day basis as a procedure for safe and effective dose finding--a pilot study in 20 patients. Support Care Cancer (1994) 1.43
Morphine intoxication during acute reversible renal insufficiency. J Palliat Care (1991) 1.43
The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. Eur J Cancer (2000) 1.43
Prognosis of isolated seizures in adult life. Br Med J (Clin Res Ed) (1981) 1.43
Short-term effect of exercise on platelet factor 4 in normal subjects and in patients with coronary artery disease. Cardiologia (1999) 1.42
Latest trends in cancer incidence among UK South Asians in Leicester. Br J Cancer (2003) 1.42
Neurilemmoma of the ciliary body: report of a case. Br J Ophthalmol (1983) 1.41
Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4'-tetramethoxystilbene. Br J Cancer (2004) 1.40
Australian multicentre phase II trial of paclitaxel in women with metastatic breast cancer and prior chemotherapy. Med J Aust (1997) 1.40
An open multicentre study of tropisetron for cisplatin-induced nausea and vomiting. Med J Aust (1996) 1.40
West Nile encephalitis in Israel, 1999: the New York connection. Emerg Infect Dis (2001) 1.39
Horizontal transmission of hepatitis B virus. Lancet (1991) 1.39
Breast cancer treatment outside teaching hospitals. Aust N Z J Med (1992) 1.38
Vapreotide, a new somatostatin analogue in the palliative management of obstructive ileus in advanced cancer. Support Care Cancer (1993) 1.38
Sinus histiocytosis with massive lymphoadenopathy (Rosai-Dorfman disease). Clinico-pathological analysis of a paediatric case. Eur J Pediatr (1992) 1.38
Ras controls growth, survival and differentiation in the Drosophila eye by different thresholds of MAP kinase activity. Development (2001) 1.37
Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study. Ann Oncol (2005) 1.37
A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Br J Cancer (2007) 1.33
Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Eur J Cancer (1996) 1.32
Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol (1995) 1.30
Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer (1998) 1.27
A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol (1987) 1.26
The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol (2000) 1.26
A group cognitive behaviour therapy programme with metastatic breast cancer patients. Psychooncology (1999) 1.25
Lack of immunoglobulin E response to longstanding strongyloidiasis. Clin Exp Immunol (1979) 1.22
Oxidative stress and cyclooxygenase activity in prostate carcinogenesis: targets for chemopreventive strategies. Eur J Cancer (2005) 1.19
Evidence for a polyclonal nature of the cell infiltrate in sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease). Br J Haematol (1995) 1.19
Plasma and urinary levels of adriamycin in man. Eur J Cancer (1972) 1.19
Splenomegalic immunocytoma with circulating hairy cells. Report of eight cases and revision of the literature. Haematologica (1986) 1.19
Early versus late chest radiotherapy for limited stage small cell lung cancer. Cochrane Database Syst Rev (2005) 1.17
Effects of dietary curcumin on glutathione S-transferase and malondialdehyde-DNA adducts in rat liver and colon mucosa: relationship with drug levels. Clin Cancer Res (2001) 1.14
Hyaluronidase as an antidote to extravasation of Vinca alkaloids: clinical results. J Cancer Res Clin Oncol (1994) 1.13
A simple, reproducible method for monitoring the treatment of tumours using dynamic contrast-enhanced MR imaging. Br J Cancer (2006) 1.12
Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer: report of a phase I/II dose-escalating study. Eur J Cancer (2000) 1.12
Chronic Strongyloides stercoralis infection in former British Far East prisoners of war. QJM (2004) 1.11
Measurements using the alkaline comet assay predict bladder cancer cell radiosensitivity. Br J Cancer (2003) 1.11
Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment. Ann Oncol (2006) 1.10
Geography of clinical cancer research publications from 1995 to 1999. Eur J Cancer (2003) 1.10
Pulmonary vein antral isolation for paroxysmal atrial fibrillation: results from long-term follow-up. J Cardiovasc Electrophysiol (2010) 1.09
"Fatigue and malaise" as a quality-of-life indicator in small-cell lung cancer patients. The Swiss Group for Clinical Cancer Research (SAKK) Support Care Cancer (1993) 1.09
Flow-cytometric DNA analysis in primary breast carcinomas and clinicopathological correlations. Cytometry (1984) 1.09
Clinical results using the trochanter stabilizing plate (TSP): the modular extension of the dynamic hip screw (DHS) for internal fixation of selected unstable intertrochanteric fractures. J Orthop Trauma (1998) 1.09
Chromosomal localisation, inducibility, tissue-specific expression and strain differences in three murine peroxisome-proliferator-activated-receptor genes. Eur J Biochem (1995) 1.08
A novel murine P-450 gene, Cyp4a14, is part of a cluster of Cyp4a and Cyp4b, but not of CYP4F, genes in mouse and humans. Biochem J (1997) 1.08
A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma. Br J Cancer (2003) 1.08
Use of Sinemet in locked-in syndrome: a report of two cases. Arch Phys Med Rehabil (1995) 1.07
Evaluation of the prognostic value of systemic inflammation and socioeconomic deprivation in patients with resectable colorectal liver metastases. Eur J Cancer (2008) 1.07
Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels. Breast Cancer Res Treat (1988) 1.07